The stratified randomization is indeed important and useful. However, given the multiple data from trials such as AVOID (Air Versus Oxygen in STEMI), do you think it would be useful to review your retrospective analysis of the patient's baseline characteristics to determine if there was a significant difference in the number of patients with MI (whether it was simply demand ischemia or not)?
I understand that the DETO2X-AMI trials didn't show hard end point differences, but I am sure your patient population is different enough and given the severity of the disease process of ARDS, it is worth looking into whether or not there was a significant difference in terms of the cardiac diseases in each arm of your trial.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.